A FORMULATION COMPRISING OF SYMPLOSOSIDE DERIVATIVES INTENDED TO SUPPRESS NUCLEOSIDE REVERSE TRANSCRIPTASE
Creators: name: Alkoclar, Erdal Can
Publisher: name: Zenodo
Year: 2020
Subjects: Reverse Transcriptase DNA Polymerase Antiviral

description: <strong>Field of Invention</strong> The present invention herewith discloses a formulation comprising of symplososide derivatives intended to suppress nucleoside reverse transcriptase. <strong>Background of the Related Technology</strong> At present it is known that a nucleoside is a compound from a group that comprises of a purine or pyrimidine base (adenine, guanine, cytosine, thymine or uracil) binding to a ribose or deoxyribose sugar, e.g. adenosine, cytidine, uridine, thymidine, guanidine. In state of art technology, invention no “EP1654270B1", with title “Process for preparing 2',3'-didehydro-2',3'-dideoxynucleosides and 2',3'-dideoxynucleosides" and under classification number “C07H 19/06" discloses a process for preparing 2',3'-didehydro-2',3'-dideoxynucleosides and 2',3'-dideoxynucleosides is described, which comprises the reductive elimination reaction of a compound of formula (I) in which X, Y, P' and B have the meanings given in the description, by reaction with zinc metal and a suitable activating agent; characterized in that the divalent zinc is removed by precipitation, from an organic phase, of the corresponding zinc sulfide, by adding a solution of a mineral sulfide to the said organic phase Again invention no “WO 1996/037214", with title “Compositions of interleukin and pyrimidine nucleosides" and under classification number “A61K 38/20" discloses a synergistic antitumor pharmaceutical composition comprising an effective amount of interleukin-12 and a pyrimidine nucleoside derivative as well as a hydrate or solvate thereof that is converted into fluorouracil or its derivative, and a pharmaceutically acceptable carrier Again invention no “EP2396340B1" and under classification number "" discloses generally the compounds with antiviral activity, more particularly nucleosides active against Flaviviridae virüs infections. To conclude it has become inevitable to proceed with a development in the area of the related technology, considering the inadequacy of the existing solutions and the need for a formulation comprising of symplososide derivatives intended to suppress nucleoside reverse transcriptase. <strong>Objective of the Invention</strong> To overcome the disadvantages experienced in state of art technology; One objective of the present invention is to ensure DNA polymerase suppression. One other objective of the invention is to ensure nucleoside reverse transcriptase suppression. One other objective of the invention is to ensure Topoisomerase type 1 and 2 suppression. The present invention which is aimed to achieve the above-mentioned advantages, is intended to suppress nucleoside reverse transcriptase and is a formulation that is obtained by combination of the compositions selected in a single form or in combinations from a group containing; 6-methoxy-symplososide, 22-dihydroxy-hexafluoro-symplososide. Structural and characteristic properties as well as all the advantages of the invention presented herewith will be clearly understood with the detailed description provided below and thus the evaluation regarding the present invention should be based on the detailed description presented herewith. <strong>Detailed Description of the Invention</strong> The present invention herewith discloses a formulation comprising of symplososide derivatives intended to suppress nucleoside reverse transcriptase. Referred formulation ensures DNA polymerase suppression, ensures nucleoside reverse transcriptase suppression, ensures Topoisomerase type 1 and 2 suppression. The formulation of the invention presented herewith contains; 6-methoxy-symplososide, 22-dihydroxy-hexafluoro-symplososide . The referred formulation is formed by mixing the above-mentioned components at below percentages by weight; 1-99% of 6-methoxy-symplososide, 99-1% of 22-dihydroxy-hexafluoro-symplososide. Components given above are obtained by combining the components from the above-mentioned group at the given range of weight ratios in a single form or in combinations thereof. The present invention at the same time discloses using the above-referred formulation comprising of symplososide derivatives intended to suppress nucleoside reverse transcriptase and manufacturing it for such purpose. <strong>CLAIMS</strong> A formulation comprising of symplososide derivatives intended to suppress nucleoside reverse transcriptase, which consists of combining the components selected from the group; 6-methoxy-symplososide, 22-dihydroxy-hexafluoro-symplososide in a single form or in combinations thereof The formulation of Claim 1 which is characterized by containing 1-99% of 6-methoxy-symplososide by weight. The formulation of Claim 1 which is characterized by containing 99-1% of 22-dihydroxy-hexafluoro-symplososide by weight. Using the compositions obtained by selecting singly or in combination of components from the group of; 6-methoxy-symplososide, 22-dihydroxy-hexafluoro-symplososide from any one as given in Claims 2-3 in manufacturing the formulation comprising of symplososide derivatives intended to suppress nucleoside reverse transcriptase. <strong>SUMMARY</strong> <strong>A FORMULATION COMPRISING OF SYMPLOSOSIDE DERIVATIVES INTENDED TO SUPPRESS NUCLEOSIDE REVERSE TRANSCRIPTASE</strong> The present invention herewith discloses a formulation comprising of symplososide derivatives intended to suppress nucleoside reverse transcriptase. Referred formulation ensures DNA polymerase suppression, ensures nucleoside reverse transcriptase suppression, ensures Topoisomerase type 1 and 2 suppression.